124 314

Cited 2 times in

Results of a Phase II Study to Evaluate the Efficacy of Docetaxel and Carboplatin in Metastatic Malignant Melanoma Patients Who Failed First-Line Therapy Containing Dacarbazine

 Choong-kun Lee  ;  Minkyu Jung  ;  Sang Joon Shin  ;  Sun Young Rha  ;  Su Jin Heo  ;  Hyun Cheol Chung  ;  Joong Bae Ahn  ;  Mi Ryung Roh  ;  Hyo Song Kim  ;  Hye Ryun Kim  ;  Hye Jin Choi 
 CANCER RESEARCH AND TREATMENT, Vol.47(4) : 781-789, 2015 
Journal Title
Issue Date
Adult ; Aged ; Antineoplastic Agents/administration & dosage ; Antineoplastic Agents/therapeutic use* ; Antineoplastic Combined Chemotherapy Protocols ; Carboplatin/administration & dosage ; Carboplatin/adverse effects ; Carboplatin/therapeutic use* ; Dacarbazine/administration & dosage ; Dacarbazine/adverse effects ; Dacarbazine/therapeutic use* ; Female ; Humans ; Male ; Melanoma/drug therapy* ; Middle Aged ; Patient Compliance ; Taxoids/administration & dosage ; Taxoids/adverse effects ; Taxoids/therapeutic use* ; Young Adult
Carboplatin ; Docetaxel ; Melanoma ; Second-line chemotherapy
PURPOSE: There is no standard second-line regimen for malignant melanoma patients with disease progression after first-line chemotherapy, and platinum-alkylating agents combined with paclitaxel have shown modest efficacy. MATERIALS AND METHODS: We conducted a phase II, open-label, single-arm study to test the efficacy of docetaxel combined with carboplatin for malignant melanoma patients who failed previous treatment with dacarbazine. Intravenous docetaxel (35 mg/m(2) on days 1 and 8 of each cycle) and carboplatin (area under the curve 3 on days 1 and 8 of each cycle) was administered every 21 days. Primary end point was objective response rate (ORR). RESULTS: Thirty patients were enrolled in the study, and the median follow-up duration was 19.8 months. Among 25 per-protocol patients, there were three responders (1 with complete response and 2 with partial response) and 17 stable disease patients (ORR, 12.0%). Among the per-protocol population, the median progression-free survival (PFS) was 4.3 months and the median overall survival (OS) was 9.6 months. Uveal melanoma patients (n=9) showed the best prognosis compared to other subtypes (median PFS, 7.6 months; OS, 9.9 months). The most common grade 3 or 4 adverse event was neutropenia (n=15, 50.0%). CONCLUSION: Docetaxel combined with carboplatin showed association with an acceptable safety profile and overall efficacy for patients with malignant melanoma who had progressed on chemotherapy containing dacarbazine.
Files in This Item:
T201510010.pdf Download
Appears in Collections:
1. College of Medicine (의과대학) > Dept. of Dermatology (피부과학교실) > 1. Journal Papers
Yonsei Authors
Kim, Hye Ryun(김혜련) ORCID logo https://orcid.org/0000-0002-1842-9070
Kim, Hyo Song(김효송) ORCID logo https://orcid.org/0000-0002-0625-9828
Roh, Mi Ryung(노미령) ORCID logo https://orcid.org/0000-0002-6285-2490
Rha, Sun Young(라선영) ORCID logo https://orcid.org/0000-0002-2512-4531
Shin, Sang Joon(신상준) ORCID logo https://orcid.org/0000-0001-5350-7241
Ahn, Joong Bae(안중배) ORCID logo https://orcid.org/0000-0001-6787-1503
Lee, Choong Kun(이충근)
Jung, Min Kyu(정민규) ORCID logo https://orcid.org/0000-0001-8281-3387
Chung, Hyun Cheol(정현철) ORCID logo https://orcid.org/0000-0002-0920-9471
Choi, Hye Jin(최혜진) ORCID logo https://orcid.org/0000-0001-5917-1400
Heo, Su Jin(허수진) ORCID logo https://orcid.org/0000-0002-0615-5869
사서에게 알리기


Items in DSpace are protected by copyright, with all rights reserved, unless otherwise indicated.